Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Stock Position Decreased by Invesco Ltd.

Invesco Ltd. reduced its holdings in shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX - Free Report) by 95.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 29,906 shares of the biotechnology company's stock after selling 626,604 shares during the period. Invesco Ltd. owned 0.05% of Aldeyra Therapeutics worth $149,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of the business. Catalyst Funds Management Pty Ltd grew its stake in Aldeyra Therapeutics by 2,083.3% in the 4th quarter. Catalyst Funds Management Pty Ltd now owns 13,100 shares of the biotechnology company's stock worth $65,000 after acquiring an additional 12,500 shares in the last quarter. U.S. Capital Wealth Advisors LLC purchased a new stake in Aldeyra Therapeutics in the 4th quarter valued at about $69,000. SG Americas Securities LLC boosted its position in Aldeyra Therapeutics by 14.4% in the 4th quarter. SG Americas Securities LLC now owns 22,365 shares of the biotechnology company's stock valued at $112,000 after buying an additional 2,822 shares during the period. Intech Investment Management LLC boosted its holdings in Aldeyra Therapeutics by 62.7% in the fourth quarter. Intech Investment Management LLC now owns 23,806 shares of the biotechnology company's stock valued at $119,000 after purchasing an additional 9,178 shares in the last quarter. Finally, Boston Financial Mangement LLC acquired a new position in Aldeyra Therapeutics in the fourth quarter valued at $141,000. 59.71% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on ALDX shares. BTIG Research dropped their target price on Aldeyra Therapeutics from $11.00 to $9.00 and set a "buy" rating for the company in a research note on Monday, April 7th. HC Wainwright reissued a "buy" rating and issued a $10.00 price target on shares of Aldeyra Therapeutics in a research note on Friday, April 4th.

Insider Activity at Aldeyra Therapeutics

In other Aldeyra Therapeutics news, major shareholder Perceptive Advisors Llc sold 3,400,000 shares of Aldeyra Therapeutics stock in a transaction on Thursday, April 3rd. The stock was sold at an average price of $1.42, for a total value of $4,828,000.00. Following the sale, the insider now owns 5,875,851 shares in the company, valued at $8,343,708.42. The trade was a 36.65 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 8.50% of the stock is owned by company insiders.

Aldeyra Therapeutics Trading Up 2.8 %

ALDX stock traded up $0.06 during midday trading on Friday, hitting $2.22. The stock had a trading volume of 698,477 shares, compared to its average volume of 763,655. The company has a current ratio of 6.80, a quick ratio of 6.80 and a debt-to-equity ratio of 0.18. The business has a fifty day moving average price of $4.07 and a two-hundred day moving average price of $4.87. The firm has a market cap of $132.97 million, a P/E ratio of -2.36 and a beta of 0.92. Aldeyra Therapeutics, Inc has a 1-year low of $1.14 and a 1-year high of $7.20.

Aldeyra Therapeutics (NASDAQ:ALDX - Get Free Report) last released its quarterly earnings data on Thursday, March 6th. The biotechnology company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.03 by ($0.30). On average, sell-side analysts predict that Aldeyra Therapeutics, Inc will post -0.92 earnings per share for the current fiscal year.

Aldeyra Therapeutics Company Profile

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.